Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

GIP: An Inconsequential Incretin or Not?

Open access
Pratley, Richard E. · 2010 · Diabetes Care

Abstract

The “incretin effect” refers to the enhancement of insulin secretion in response to an oral glucose load relative to that of an isoglycemic intravenous glucose challenge (1). In humans, the incretin effect is mediated by two peptide hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are secreted from enteroendocrine cells in response to nutrients entering the gut. GLP-1 secretion from L-cells, found in highest density in the distal ileum but also throughout the small and large intestine, is stimulated by glucose, amino acids, and fat. GIP, in contrast, is produced by the K-cells in the proximal duodenum; its secretion is also stimulated by glucose, but is particularly enhanced by fat (2). Both GLP-1 and GIP are derived from prohormones (proglucagon and pro-GIP, respectively) and secreted as active hormones. The effects of both GLP-1 and GIP are mediated by specific G protein–coupled receptors present on the plasma membrane of β-cells and other target tissues. GLP-1 and GIP increase insulin secretion from β-cells in a glucose-dependent manner. In rodents, GLP-1 and GIP also enhance β-cell mass by increasing rates of proliferation and decreasing rates of apoptosis. Many physiological effects of GLP-1 and GIP do not overlap, however. GLP-1 suppresses glucagon secretion, slows gastric emptying, and has central nervous system effects to regulate appetite, whereas GIP does not. GIP, on the other hand, has direct effects on adipocytes to promote triglyceride storage (1). The incretin system, therefore, facilitates integrated physiological responses to meals of different size and composition allowing ingested nutrients to be optimally metabolized. The incretin effect is an important determinant of glucose tolerance. In patients with type 2 diabetes, the incretin effect …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc10-0704

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 12 · Cited by 19

Metadata

Authors
Pratley, R. E.
Affiliations
University of Vermont (US)
Corresponding author
Pratley, Richard E.
Venue
Diabetes Care
Published
2010-07-01
Volume
33
Issue
7
Pages
1691-1692
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2145489764
Cited by
19
References
12
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2017: 1 · 2016: 1 · 2012: 1
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
glucose-dependent insulinotropic polypeptide, incretin effect, glucagon-like peptide-1, insulin secretion, enteroendocrine cells, beta-cell proliferation, type 2 diabetes, glucose tolerance, glucagon suppression, gastric emptying, appetite regulation
MeSH terms
Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Glucose Intolerance, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GIP: An Inconsequential Incretin or Not? https://app.cochat.ai/papers/10.2337/dc10-0704
The paper
Pratley, R. E. (2010). GIP: An Inconsequential Incretin or Not? Diabetes Care. https://doi.org/10.2337/dc10-0704

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.